Credit Suisse Maintains Underperform on REV Group, Lowers Price Target to $11
Credit Suisse analyst Jamie Cook maintains REV Group (NYSE:REVG) with a Underperform and lowers the price target from $12 to $11.
REV Group’s Return On Capital Employed Overview
Pulled from Benzinga Pro data, REV Group (NYSE:REVG) showed a loss in earnings since Q4, totaling $700.00 thousand. Sales, on the other hand, increased by 8.97% to $537.00 million during Q1.
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell
• REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.
REV Group Delivers All-Electric, Zero-Emission Ambulance To DocGo
REV Group Inc (NYSE:REVG) delivered an all-electric, zero-emission ambulance to DocGo, a provider of last-mile mobile health services and integrated…
REV Ambulance Group Company Delivers All-Electric, Zero-Emission Ambulance To DocGo
BROOKFIELD, Wis.--(BUSINESS WIRE)-- REV Group, Inc. (NYSE:REVG) which includes companies that manufacture Horton®, AEV®, Road Rescue®, Wheeled Coach® and Leader® brand ambulances, announces the
REV Group Subsidiary ElDorado National Highlights First Order Of 6 Axess Battery Electric Zero Emission Buses, No Terms Disclosed
ElDorado National (California) or ENC, a subsidiary of REV Group® and an industry leader in heavy-duty transit buses and emission-free technology, announces the first order for six Axess Battery Electric Bus (BEB),
Goldman Sachs Maintains Sell on REV Group, Lowers Price Target to $13.25
Goldman Sachs maintains REV Group (NYSE:REVG) with a Sell and lowers the price target from $15.5 to $13.25.
REV Group’s Return on Invested Capital Insights
Pulled from Benzinga Pro data REV Group (NYSE:REVG) saw a drop in both earnings and sales after Q4. Earnings dropped to $0.00, a 100.0% decrease from the previous quarter. Sales fell to $589.90 million, down 0.57% from the previous quarter.
Morgan Stanley Maintains Equal-Weight on REV Group, Lowers Price Target to $13
Morgan Stanley maintains REV Group (NYSE:REVG) with a Equal-Weight and lowers the price target from $17 to $13.
46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.